SRPT•Sarepta Therapeutics’ third-quarter 2026 net loss narrowed 44% year over year to $28.5 million, while revenue fell 5% to $381.4 million. The company expects DM1 and FSHD multiple ascending dose data in the fourth quarter of 2026.
Sarepta Therapeutics’ third-quarter 2026 net loss narrowed 44% year over year to $28.5 million. Revenue fell 5% to $381.4 million, primarily due to lower ELEVIDYS sales volumes following its restriction to ambulatory patients. Research and development expenses dropped 62% to $82.5 million, primarily reflecting a $100 million Arrowhead milestone payment in the prior-year quarter.
DM1 and FSHD multiple ascending dose data are expected in the fourth quarter of 2026, with Phase 3 preparations underway.
